17 February 2021

Tom Nijenhuis and Jeroen de Baaij, theme Renal disorders, received a Dutch Kidney Foundation Innovation grant together with colleagues from ErasmusMC and AmsterdamUMC for their project “A sweet deal: repurposing SGLT2i for renal hypomagnesemia”.

Renal hypomagnesemia occurs in rare kidney disorders like ADTKD-HNF1b and Gitelman syndrome, but is also a side-effect of several widely-prescribed drugs. Hypomagnesemia can result in chronic fatigue, muscle weakness, neurological symptoms and neurocognitive deficits. The only treatment option is magnesium supplementation, which has dose-limiting gastrointestinal side-effects most often leading to insufficient correction of serum magnesium and persistence of symptoms.

SGLT2 inhibitors, used to treat diabetes, have pleiotropic effects which also appears to include a renal magnesium-sparing potential. Case reports suggests that this beneficial effect may be considerable in particular in renal hypomagnesemia. On the one hand, the researchers will perform N-of-1 trials in patients with a rare renal hypomagnesemia to study the effect of SGLT2 inhibition on serum magnesium and symptoms. On the other hand, they will study the molecular mechanism of the magnesium-sparing action of SGLT2 inhibition in animal studies.

Jeroen de Baaij is assistant professor at the department of Physiology studying the genetic and molecular origins of electrolyte disorders, including magnesium wasting. Tom Nijenhuis is internist-nephrologist at the department of Nephrology focusing on the pathogenesis and treatment of rare kidney disorders, including magnesium-wasting tubulopathies.

Related news items


ADP/ATP carrier inhibitor characteristics identified

3 March 2021

Tom Schirris and colleagues, published an article entitled “Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition” in Theranostics.

read more

Water as a new tool for cardiac screening for chest pain

2 March 2021

Patients with chest pain not caused by a narrowing of the coronary arteries often do not know the cause of their symptoms. Scientists at the Radboudumc have successfully used a new technique to investigate other causes in the coronary arteries of the heart.

read more

Reducing sitting time improves blood flow in the brain and in the legs

2 March 2021

During a regular day, the average person sits for 8-10 hours. These high levels of sitting time seem linked to an increased risk for both cardiovascular and cerebrovascular diseases.

read more

Real-time dialogue with a dreaming person is possible

25 February 2021

Dreams take us to what feels like a different reality. They also happen while we're fast asleep. So, you might not expect that a person in the midst of a vivid dream would be able to perceive questions and provide answers to them. But a new international study shows that, in fact, they can.

read more

Vulnerable Nijmegen citizens less likely to visit GP physically due to corona

23 February 2021

The COVID-19 pandemic in 2020 in Nijmegen and the surrounding area led to a substantial decrease in GP consultations for patients with chronic physical health problems.

read more

SATB1 - Three classes of mutations and their unique rare diseases

18 February 2021

Recent advances in DNA sequencing technologies have made it possible to uncover the causes of multiple rare diseases. A new collaborative study describes how three classes of mutation within the same gene result in different neurodevelopmental disorders.

read more